Derma Sciences to Report 2008 Fourth Quarter and Year-End Results on April 1, 2009

Derma Sciences to Report 2008 Fourth Quarter and Year-End Results on April 1,
2009

PRINCETON, N.J., March 24 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC
Bulletin Board: DSCI), a provider of advanced wound care products, announced
today that it will report its fourth quarter and year-end 2008 results on
Wednesday, April 1, 2009. The Company will hold a conference call that same
day to discuss the results at 11:00 am EDT. Interested parties should call
866-271-5140 (domestic) or 617-213-8893 (international), with passcode
42480759 to access the call. You may also access this call via the Internet
at:

http://phx.corporate-ir.net/playerlink.zhtml?c=107533&s=wm&e=2119681

For those who are unavailable to listen to the live broadcast, a replay will
be available through May 1, 2009 and can be accessed by dialing 888-286-8010
(domestic), and 617-801-6888 (international). The passcode is 36656033.

About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound-care
products. Its key product, MEDIHONEY(TM), is sold throughout the world by
Derma Sciences and Comvita New Zealand -- the licensor of the patented
honey-based technology -- and is the leading brand of honey-based dressings
for the management of wounds and burns. The product has been shown to be
effective in a variety of wounds and burns, and was the focus of a positive
large-scale randomized controlled trial on leg ulcers. Derma's recently FDA
cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product
entrant into the $14 billion global wound care market. The barrier technology
was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has
in development DSC127, a novel angiotensin analog for accelerated wound
healing and scar reduction. DSC127 was licensed from the University of
Southern California in Q4 of 2007. Patient enrollment for a Phase II study
began in Q4 of 2008. Results from this study are expected to be submitted to
the FDA in Q2 of 2010. For more information about Derma Sciences, Inc., visit
http://www.dermasciences.com.

Contact:

Derma Sciences, Inc.
Edward J. Quilty
Chairman and CEO
equilty@dermasciences.com
(609) 514-4744

Allen & Caron Inc
Rudy Barrio (US Investors)
r.barrio@allencaron.com
(212) 691-8087

Brian Kennedy (Media)
brian@allencaron.com
(212) 691-8087

SOURCE Derma Sciences, Inc.

Edward J. Quilty, Chairman and CEO of Derma Sciences, Inc., +1-609-514-4744,
equilty@dermasciences.com; or US Investors, Rudy Barrio, +1-212-691-8087,
r.barrio@allencaron.com, or Media, Brian Kennedy, +1-212-691-8087,
brian@allencaron.com, both of Allen & Caron Inc, for Derma Sciences, Inc.